This funding, provided through the NIH’s Somatic Cell Genome Editing Program, will support gene-editing research aimed at ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...

Gene-editing therapies—techniques that modify DNA to treat or prevent disease—have the potential to transform the field of ...

As Shift Bioscience raises $16 million in seed funding, delve into the field of cellular reprogramming to tackle age-related ...

An exploration of AI's transformative potential according to Dario Amodei, highlighting its risks to democracy and the ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...

The ultimate goal is to enable improved design of gene therapy approaches with the aim of life-long correction across a range ...

KFSHRC is also advancing genomic medicine with CRISPR-Cas9 gene editing and personalized cancer therapies, including the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Researchers obtain detailed picture of the specific mechanisms by which each individual mutation studied impacts drug response.